{"analyses":[{"ciLowerLimit":"0.529","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.797","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.93","paramType":"Hazard Ratio (HR)","paramValue":"0.975","statisticalComment":"Stratified log-rank test","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"groups":[{"description":"Participants received thalidomide every night (at bedtime) without food on Days 1 to 28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 to 7, 100 mg on Days 8 to 14, 150 mg on 15 to 21, and 200 mg on Days 22 to 28. Thalidomide 200 mg per day was administered for subsequent cycles. Dexamethasone 40 mg was administered by mouth on Days 1 to 4, 9 to 12 and 17 to 20.","id":"OG000","title":"Thalidomide + Dexamethasone"},{"description":"DOXIL 40 mg/m2 was administered intravenously on Day 1 and thalidomide every night (at bedtime) without food on Days 1-28 and dosing was gradually increased during Cycle 1 starting at 50 mg on Days 1 to 7, 100 mg on Days 8 to 14, 150 mg on 15 to 21, and 200 mg on Days 22 to 28. Thalidomide 200 mg per day was administered for subsequent cycles. Dexamethasone 40 mg was administered by mouth on Days 1 to 4, 9 to 12 and 17 to 20.","id":"OG001","title":"DOXIL + Thalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat: Participants who were randomized to receive the treatment.","reportingStatus":"POSTED","timeFrame":"From randomization until death or as assessed up to 2 years post last participant last treatment visit","title":"Overall Survival: Number of Participants Died Due to Any Cause","type":"SECONDARY","unitOfMeasure":"Participants"}